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There is a paucity of data regarding molecular subtypes of pure ductal carcinoma in situ (pDCIS). We evaluated the expression
of ER, PR, HER2, Ki67, and p53 and DNA ploidy in 118 pDCIS and 100 invasive breast carcinomas (IBCAs) by routine IHC and
classiﬁed them according to molecular subtypes. Quantiﬁcation of biomarkers and DNA ploidy was performed by image analysis.
Expression of ER, PR, and high ki67 was more frequent in pDCIS compared to IBCA. High-grade tumors had lower ER and PR
expression,highKi67,overexpressionofHER2andp53,andDNAaneuploidy.LuminalAandHER2subtypesweremorecommon
in pDCIS, and triple negative was more prevalent in IBCA. In both groups, HER2 and triple negative subtypes were characterized
by high ki67, overexpression of p53, and DNA aneuploidy compared to luminal subtypes. Molecular subtypes of IBCA are distinct
from those of pDCIS. Invasion is characterized by change in phenotype in some tumors.
1.Introduction
Ductal carcinoma in situ (DCIS) is a complex disease with
diverse clinical presentation, histologic subtypes, and bio-
logic behavior [1]. Although DCIS is considered a direct pre-
cursor of invasive carcinoma, the rate of progression is high-
ly variable with some types of DCIS progressing faster than
others. The conventional parameters such as histologic pat-
terns, nuclear grade, and presence of necrosis are used for
grading and determining prognosis in DCIS [1–3]. However,
morphologic features alone do not reﬂect the true biology of
thisdisease.Theidentiﬁcationofmarkersthatcanpredictre-
currence and/or invasion in DCIS is critical. Some studies
have showed that expression of ER, PR, HER2, Ki67, and p53
c o r r e l a t ew i t ht u m o rg r a d er a t h e rt h a ni n v a s i o n[ 1–5].
Gene expression analysis has demonstrated several mol-
ecular subtypes of IBCA; these include the luminal A, lumi-
nalB,HER2,andtriplenegative/basalsubtypes[6,7].Recent
studies have shown that expression of ER, PR, and HER2
by IHC can be used as a surrogate tool for the molecular
subtyping of IBCA [8, 9]. Proliferation is an important com-
ponent in the molecular classiﬁcation of IBCA [8, 10, 11].
The MKi67 gene encodes the Ki67 protein, a robust marker
of cell proliferation and a predictor of poor outcome [11].
While the molecular subtypes of IBCA have been well
characterized, far less is known about the biologic subtypes
of pDCIS. A detailed analysis of biomarker expression in
pDCIS has not been well documented, and there are very few
studies that have compared biomarker expression and mol-
ecular subtypes in pDCIS with IBCA. There is a paucity of
data regarding the relationship of the molecular subtypes
with tumor grade, Ki67 and p53 expression, and DNA ploidy
[9, 12].
In the present study, we performed a comparative analy-
sis of biomarkers (ER, PR, HER2, Ki67, and p53) expression
and DNA ploidy in pDCIS and IBCA by automated image2 International Journal of Breast Cancer
analysis using whole tumor sections and determined if there
were quantitative diﬀerences in their expression in the two
groups. We also attempt to classify pDCIS and IBCA accord-
ing to molecular subtypes using IHC as proxy for gene ex-
pression and to determine if there were any diﬀerences in the
prevalence of the subtypes in the two groups. We also inves-
tigated the relationship of Ki67 index, tumor grade, DNA
ploidy, and p53 overexpression with molecular subtypes of
pDCIS and IBCA.
2.MaterialsandMethods
This retrospective study consists of 118 consecutive patients
witha diagnosis ofpDCIS and 100 consecutive casesofIBCA
on ﬁnal surgical excision. Patient demographics, tumor size,
and types of surgery were extracted from the electronic
medical records of UT Southwestern Medical Center and
Parkland Health and Hospital Systems after approval by the
Institutional Review Board. All pathology data was obtain-
ed from electronic laboratory information system of the De-
partment of Pathology. Grading of DCIS and IBCA was per-
formed using the World Health Organization (WHO) cri-
teria into low (grade 1), intermediate (grade 2), and high
(grade 3). Size of DCIS was determined by the extent of the
lesion in consecutive sections or by the number of involved
sections and gross measurement. The architectural patterns
of DCIS were also recorded, and comedo necrosis was eval-
uated as a separate parameter but was not quantitated. Grad-
ing of IBCA was done using the modiﬁed Bloom-Richardson
Nottingham scoring system.
Biomarker expression and DNA ploidy were prospec-
tively performed as part of the patient’s clinical workup. As
a matter of routine, the most representative tumor section
was selected for biomarker analysis. In patients with IBCA,
paraﬃnblockwithpredominantlyinvasivetumorwasselect-
ed and image analysis was performed only on the invasive
tumor, regardless of the presence or absence of in situ
component.
2.1. Immunohistochemistry (IHC) and Image Quantitation of
Biomarker Expression. Slides were stained on an automated
immunostainer (Dako autostainer, Carpentaria, CA). Mon-
oclonal antibodies from the Dako Medical Systems, Carpen-
teria, CA were used for ER (clone 1D5, 1:800), PR (PgR 636,
1:1000) and Ki67 (MIB-1, 1:300), HER2/neu (1:600), and
p53 (DO-7, 1:2200, Dako, Carpenteria, Calif, USA). Scoring
and quantiﬁcation of ER, PR, Her2/neu, p53, and ki67 was
performed on the most representative area of the tumor
using the computerized Automated Cellular Imaging System
(ACIS, Clarient, Inc. San Juan Capistrano, Calif, USA). The
ACIS system consisted of an automated robotic bright-
ﬁeld microscope module, a computer, and a Windows-NT-
based software interface. Subregions were selected from the
digital images of the IHC-stained slides for analysis. Positive
staining in 5% or more of the tumor cells for ER and
PR in 10 selected subregions of the tumor was scored as
positive for ER and PR expression. The results of ER and
PR were reported as percent of positive staining nuclei, and
stainingintensity wasgradedfrom1+to3+.ToassessHER-2
overexpression,ACISprovidedanaveragescorefor5selected
subregions of the tumor with the highest cytoplasmic mem-
brane staining intensity for HER-2. Tumors with more than
1 0 %c e l l swi t ha na v e ra g es c o r e≥2 . 0w e r ec o n s i d e r e dt oh a v e
HER-2 overexpression, this was equivalent to a 3+ positive
staining by manual scoring. Scores between 1.4 and 1.9 were
reported as borderline (or 2+ by manual scoring), and <1.4
were reported negative. Computer-generated results were
conﬁrmed by manual review by pathologists with experience
in image analysis. Tumors with ER and PR scores of less
than 5% were considered negative expression. All cases with
positive or borderline HER-2 results on IHC were conﬁrmed
by ﬂuorescent in situ hybridization (FISH) using the FDA
approved PathVysion kit (Abbott-Vysis Lab Abbott Park, Ill,
USA)accordingtothemanufacturer’sprotocol.Brieﬂy,dual-
color FISH was performed with the HER2 probe labeled
with spectrum red and chromosome 17 speciﬁc centromere
(D17Z1) probe labeled with spectrum green on deparaﬃn-
ized tumor sections cut from the same block. Fluorescent
signals in at least 60 nonoverlapping interphase nuclei with
intact morphology were scored with ×100 objective, using
a ﬂuorescence microscope. Only tumor cells from the area
designated on the H&E slide by the pathologist were scored
for the number of red (HER-2) and green (chromosome 17)
signals. A ratio of the number of ﬂuorescent signals of HER-
2 to chromosome 17 greater than 2.0 was reported as HER2
ampliﬁed.
The Ki67 index of >10% was considered to be signiﬁcant.
P53 expression in >10% of the tumor cells were considered
as overexpression. Bcl-2 immunostaining was performed in
the pDCIS cases but not on the invasive group.
2.2. DNA Ploidy Analysis. DNA analysis was performed by
imageanalysisusingFeulgenDNAstainsonparaﬃnsectio ns
from the same tumor block that was used for biomarker
analysis. DNA indices and ploidy were analyzed using the
Autocyte Pathology Workstation (Tripath, Burlington, NC,
USA). Brieﬂy, a total of 200–300 nuclei were collected was
and mean DNA index reported for each patient. DNA index
was obtained by measuring the optical density of tumor cells
in comparison with those of the nonneoplastic stromal cells
in the sample using the latter as the diploid reference (value
of 1.0). Tumors were classiﬁed into diploid and aneuploid/
multiploid based on the DNA indices.
2.3. Molecular Classiﬁcation of pDCIS and IBCA Using IHC.
Pure DCIS and IBCA were classiﬁed according to the molec-
ular subtypes. We used the Ki67 score of 14% as the cut- oﬀ
for distinguishing luminal A (ER+, PR±,H E R 2 −,K i 6 7<
14%) and luminal B (ER+, PR±,H E R 2 −,K i 6 7≥ 14%)
subtypes;luminal-Her2(ER+,PR±,HER2+);HER2+(ER−/
PR−/HER2+) and triple negative (ER−/PR−/HER2−). The
relationship of the molecular subtypes with tumor grade,
Ki67 index, p53, and DNA ploidy was analyzed. Quantitative
expression of ER, PR, HER2, Ki67, and p53 by image analysis
was correlated with tumor grade in both the pDCIS and
IBCA groups. We also compared tumor grade and ploidy
with luminal (luminal A, B, lum-HER2) versus nonluminal
(HER2 and triple negative) types.International Journal of Breast Cancer 3
Table 1: Comparison of clinicopathologic parameters in pDCIS
versus IBCA.
Variables pDCIS
(n = 118) IBCA (n = 100) P value∗
Age (mean) 61.4 ± 1.03 61.8 ± 0.87 NS
Tumor size (mean) 2.95 ± 0.23 3.37 ± 0.32 NS
Tumor grade
Low 9 (7.6%) 11 (11%) NS
Intermediate 46 (38.9%) 49 (49%) NS
High 63 (53.3%) 40 (40%) 0.0570
∗Chi-square test.
NS: not signiﬁcant.
Statistical analysis was performed by one-way ANOVA
test followed by Tukey post hoc for comparison of continu-
ousdataandFisher’sexacttestandChi-squareforcategorical
data.Thetwo-wayANOVAwithBonferroniposthoctestwas
used for comparing Ki67 in the diﬀerent subtypes of pDCIS
and IBCA using the Prism 5 software (Graphpad Software
Inc, San Diego, Calif, USA).
3. Results
3.1. Comparison of Biomarker Expression in pDCIS versus
IBCA. The mean age, tumor size, and grade were similar
in the two groups (Table 1). The frequency of expression
of diﬀerent biomarkers in the two groups is summarized in
Table 2. In pDCIS, ER, and PR expression was signiﬁcantly
higher as compared to IBCA (P = 0.007 and P = 0.005,
resp.). Although HER2 overexpression was higher in pDCIS
compared to IBCA, the diﬀerence was not statistically sig-
niﬁcant (P = 0.285). Ki67 scores of >10% was signiﬁcantly
higher in IBCA compared to pDCIS group (P = 0.003).
Overexpression of p53 (>10%) was more frequent in IBCA;
however, the diﬀerence was not statistically signiﬁcant.
3.2. Comparison of Biomarker Expression and DNA Ploidy
with Histologic Grade of pDCIS (Table 3). Expression levels
of ER and PR decreased signiﬁcantly with increasing tumor
grade (P = 0.003 and P = 0.004, resp.). HER2 overex-
pression was absent in low-grade DCIS. It was positive in
6 of 46 (13%) of intermediate grade and 28 of 63 (44%) of
high-grade DCIS (P = 0.0007). The mean HER2 gene copy
number by FISH was 5.89 in high grade compared to 4.47
in the intermediate-grade group, P = 0.30. Comedo necrosis
waspresentin 75%(27/36) ofHER2positive casescompared
to 67% (55/82) in HER2 negative (67.0%), P = 0.51. The
Ki67 scores increased signiﬁcantly with higher grades of
DCIS (P = 0.0002). Bcl-2 expression decreased signiﬁcantly
with increasing DCIS grade (P = 0.001). Overexpression of
p53 was also more frequent in high-grade Pdcis, compared
to low grade (P = 0.002).
Tumor DNA content was diploid in 38/55 (69%) of
grade 1-2 pDCIS and 47/63 (74.6%) of grade 3 pDCIS were
aneuploid (P<0.0001).
3.3. Comparison of Histologic Grades of IBCA with Biomarker
Expression and DNA Ploidy (Table 4). In the IBCA group,
Table 2: A comparison of biomarker expression in pDCIS versus
IBCA.
Tumor
biomarkers pDCIS IBCA P value∗
ER+ 97 (82.2%) 66 (66%) P = 0.0077
ER− 21 (17.7%) 34 (34%)
PR+ 81 (68.6%) 50 (50%) P = 0.0057
PR− 37 (31.3%) 50 (50%)
HER2+ (FISH) 36 (30.5%) 23 (23%) P = 0.2859
HER2− 82 (69.4%) 74 (74%)
Ki67 > 10% 78 (66.1%) 84 (84%) P = 0.0030
Ki67 < 10% 40 (33.8%) 16 (16%)
P53 >10% 27 (22.8%) 26 (26%) P = 0.6363
P53 <10% 91 (77.1%) 74 (74%)
Total 118 100
∗Chi-square test; P<0.05 is signiﬁcant.
ER and PR scores decreased signiﬁcantly with increasing
tumor grade (P<0.0001 and P = 0.005, resp.). The mean
HER2 gene ampliﬁcation ratios by FISH were 3.3, 5.2, and
4 . 3i ng r a d e s1 ,2 ,a n d3I B C Ar e s p e c t i v e l y ,a n dt h i sw a sn o t
statistically signiﬁcant. Grade 3 IBCA showed signiﬁcantly
higher p53 overexpression compared to grade 1 and 2 IBCA
(P = 0.018). The Ki67 index increased signiﬁcantly with
tumor grade (P<0.0001). Grade 1 and 2 IBCA, 29/34
(85.2%) had diploid DNA, and 35/66 (53.0%) of grade 3
tumors were aneuploid (P = 0.0002).
3.4. Comparison of Molecular Subtypes of pDCIS and IBCA
by IHC (Table 5). The prevalence of the subtypes diﬀered
signiﬁcantly in the two groups. Luminal A was more
common in pDCIS compared to IBCA (P = 0.011), and
triple negative subtype was higher in IBCA (P<0.0001).
HER2 subtype was higher in pDCIS than IBCA, but this was
not statistically signiﬁcant (P = 0.225).
TheluminalversusnonluminalpDCISandIBCAshowed
signiﬁcant association with tumor grade. In the pDCIS
group, luminal tumors were frequently of lower grade (grade
1 and 2), 51/97 (52%), and nonluminal tumors were more
likely to be grade 3, 17/21 (80.9%), P = 0.007. Similarly,
in the IBCA group, luminal tumors were predominantly of
lower grade, 48/63 (76.1%), and nonluminal were frequently
of high grade, 23/33 (69.6%), P<0.0001.
The pDCIS molecular subtypes showed signiﬁcant asso-
ciationwithDNAploidy;luminaltumorsweremorelikelyto
have diploid DNA, 53/97 (54.6%), and non luminal tumors
were frequently aneuploid, 20/21 (95.2%), P<0.0001. Sim-
ilar association was seen in the IBCA group; luminal tumors
were mostly diploid, 30/66 (45.4%), and non luminal sub-
types were frequently aneuploid/multiploid, 28/33 (84.8%),
P = 0.0035.
AcomparisonofKi67indexandp53overexpressionwith
the diﬀerent subtypes is shown in Table 6. Ki67 index in-
creased signiﬁcantly in luminal B, lum-HER2, HER2, and
t r i p l en e g a t i v ei np D C I S( P<0.0001) and IBCA (P<
0.0001). A signiﬁcant association with p53 overexpression4 International Journal of Breast Cancer
Table 3: The relationship of pDCIS grade with quantitative biomarker expression.
Variables DCIS GRADE P value (ANOVA)
No. of cases Grade 1 (9) Grade 2 (46) Grade 3 (63)
ER score (%) 89.7 ± 8.99 80.9 ± 4.78 58.6 ± 5.46 P = 0.0037
PR score (%) 62.0 ± 14.3 53.1 ± 5.42 31.9 ± 4.69 P = 0.0047
Ki67 (%) 12.7 ± 2.61 12.8 ± 1.38 25.6 ± 2.54 P = 0.0002
P53 (%) 10.0 ± 5.05 8.83 ± 3.11 21.0 ± 4.03 P = 0.0029
BCL-2 (%) 93.8 ± 6.25 75.7 ± 5.78 44.5 ± 6.78 P = 0.001
Table 4: Relationship of tumor grade with quantitative biomarker expression in IBCA.
Variables IBCA grade P value (ANOVA)
grade Grade 1 (11) Grade 2 (49) Grade 3 (40)
ER-score (%) 84.4 ± 8.80 75.3 ± 5.18 29.65 ± 6.69 P<0.0001
PR-score (%) 49.1 ± 13.6 35.16 ± 5.34 14.30 ± 4.71 P = 0.0051
Ki67 (%) 14.7 ± 2.40 29.71 ± 3.55 61.2 ± 4.17 P<0.0001
P53 (%) 11.8 ± 8.23 10.39 ± 3.26 27.95 ± 6.26 P = 0.0180
Table 5: The prevalence of the molecular subtypes in pDCIS versus
IBCA by IHC.
Molecular
subtypes Pure DCIS IBCA P value
Luminal-A 44 (37.3%) 21 (21%) 0.0113
Luminal-B 31 (26.3%) 30 (30%) 0.5490
HER2∗ 36 (31%) 23 (23%) 0.2252
Triple negative 7 (6%) 26 (26%) <0.0001
Total 118 100
∗Luminal-HER2 and HER2 subtypes are combined together as one group.
was also noted for both pDCIS (P = 0.0014) and IBCA (P<
0.0001). The lum-HER2, HER2, and triple negative subtypes
ofinvasivetumorshadsigniﬁcantlyhigherKi67proliferation
indices compared to similar subtypes of pDCIS (two-way
ANOVA and Bonferroni post hoc test (P<0.01), Table 7).
4. Discussion
In the current study, biomarker expression was performed
prospectively on whole tumor sections at the time of the pa-
tient’s diagnosis. Previous studies on biomarker expression
were performed retrospectively on tissue microarray ob-
tained from archived tumor blocks [9, 13]. We used auto-
mated image analysis for quantiﬁcation of biomarker expres-
sion. The advantage of this technique is the consistency of
results with less intra- and interobserver variability com-
pared to manual estimation [14–16]. Several studies have
shown excellent correlation between manual and automated
analysis of biomarker expression in breast cancer [14–16].
In our study, semiquantitative analysis of ER and PR levels
demonstrated signiﬁcant inverse relationship with tumor
gradein bothpDCISandIBCA. Previousstudieshaveshown
that ER and PR status is inversely correlated with tumor
grade; however, quantiﬁcation was not performed [1–4, 13,
17]. Furthermore, we have shown that the expression of ER
andPRinpDCISwassigniﬁcantlyhighercomparedtoIBCA.
This is in contrast to previous studies where the expres-
sion was found to be higher in IBCA than DCIS using tis-
sue microarray [4, 9]. Unlike whole tumor sections, tissue
microarray may lead to sampling error especially in tumors
with heterogeneous expression [18]. Also the cutoﬀ limit for
deﬁning positive expression may produce diﬀerent results
dependingonthepositivethresholdusedinthestudy.Higher
tumor grade was also associated with HER2 overexpression
in both pDCIS and IBCA consistent with previous ﬁndings
[2, 4, 9, 12, 13, 17].
There are very few studies that have compared molecular
subtypesofpDCISandIBCA[9,17].Inthepresentstudy,we
have demonstrated that the prevalence of the subtypes dif-
fered signiﬁcantly in the two groups. In pDCIS, the luminal
A was the most common (37%) followed by HER2 (31%)
and luminal B (26%); the triple negative subtype was the
least common (6%). In contrast, in the IBCA group, luminal
B was the most common (30%) followed by triple negative
(26%) and HER2 subtypes (23%). In both groups, luminal
A tumors were predominantly of low nuclear grade, with
low ki67 index, negative p53, and HER2 overexpression.
Additionally,thesetumorswerefrequentlydiploidcompared
to nonluminal tumors. Luminal A tumors originate from
diﬀerentiated luminal progenitor cells characterized by high
ER/PR and Bcl-2 expression [19]. The signiﬁcantly higher
prevalence of luminal A in pDCIS compared to IBCA may be
partly attributed to an increase in screening mammography
which may have resulted in higher rates of detection of
these very early lesions. The incidence of pDCIS has increas-
ed signiﬁcantly over the past decade due to screening mam-
mography [20]. Another possibility is that some of the low-
g r a d e( l u m i n a lA )D C I Sm a yn o tp r o g r e s st oI B C Ad u r i n g
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Table 6: A comparison of Ki67 indices and p53 overexpression in the diﬀerent subtypes of pDCIS and IBCAs.
Tumor type Luminal-A Luminal-B Lum-HER2 HER2 Triple negative P value (ANOVA)
DCIS 44 (37.3%) 31 (26.3%) 22 (8.6%) 14 (11.8%) 7 (6%)
Ki67 (%) 6.98 ± 0.52 23.8 ± 2.22 23.27 ± 2.72 33.57 ± 4.87 39.57 ± 13.6 P<0.0001
P53 (%) 7.02 ± 2.89 12.3 ± 3.92 17.8 ± 6.10 24.4 ± 8.53 52.3 ± 18.6 P = 0.0014
IBCA 21 (21%) 30 (30%) 15 (15%) 8 (8%) 26 (26%)
Ki67 (%) 7.05 ± 0.75 33.7 ± 2.53 41.4 ± 6.50 58.0 ± 9.46 67.5 ± 6.04 P<0.0001
P53 (%) 2.15 ± 0.81 6.87 ± 2.12 36.3 ± 10.1 23.1 ± 15.1 31.0 ± 8.04 P<0.0001
Table 7: Comparison of mean Ki67 indices in molecular subtypes
of pDCIS and IBCA.
subtypes Ki67 Ki67 P value
DCIS IBCA
LUMINAL-A 6.98 ± 0.52
(n = 44)
7.05 ± 0.75
(n = 21) P>0.05
LUMINAL-B 23.8 ± 2.22
(n = 31)
33.76 ± 2.53
(n = 30) P>0.05
LUM-HER2 23.27 ± 2.72
(n = 22)
41.67 ± 6.50
(n = 15) P<0.01
HER2 33.57 ± 4.87
(n = 14)
58.00 ± 9.46
(n = 8) P<0.01
TRIPLE NEG 39.57 ± 13.64
(n = 7)
67.52 ± 6.04
(n = 26) P<0.01
∗P value calculated by two-way ANOVA followed by Bonferroni post hoc
test.
The prevalence of luminal B subtype was similar in both
pDCIS and IBCA. Tamimi et al. showed that luminal B
subtype was more frequent in pDCIS compared to IBCA [9].
In their study, the classiﬁcation of luminal tumors was based
on the criteria used in Carolina Breast Cancer Study [22]i n
which luminal B tumors were deﬁned by the coexpression of
ER and HER2. In our study, we used Cheang et al.’s crite-
ria [11] for classifying luminal tumors, which also takes
into account the Ki67 index besides ER, PR, and HER2 ex-
pression. According to their study, the best Ki67 cutoﬀ value
for diﬀerentiating luminal A from B tumors was 14%. It
has been shown that the MK167 gene that encodes the Ki67
protein was highly expressed in luminal B tumors [6, 7, 10,
11].LuminalBtumorsthatcoexpressedHER2wereclassiﬁed
as luminal-HER2. This subtype comprised only 30% of the
luminal B tumors [11]. Some authors believe that luminal B
tumors are negative for HER2 [23].
In the current study, there was a trend towards higher
prevalence of HER2-positive pDCIS (31%) compared to
IBCA (23%). Several studies have demonstrated signiﬁcantly
higher HER2 overexpression in pDCIS compared to IBCA
[4, 9, 12, 13, 17]. However, in most of these studies, testing
for HER2 was performed by IHC only and the criteria
for HER2 overexpression were much lower compared to
standard guidelines. In our study, tumors with HER2 scores
of 2+ and 3+ by IHC were also conﬁrmed by FISH analysis
and only HER2-ampliﬁed tumors were considered positive.
Since FISH is the gold standard for HER2 testing, we believe
that our ﬁndings reﬂect the true prevalence of HER2 in our
study population. Studies of HER2 ampliﬁcation by FISH
have also shown higher ampliﬁcation in pDCIS compared to
IBCA [24, 25].
The clinical signiﬁcance of HER2 overexpression in
DCIS is not known at this time. Some suggests that HER2
overexpression in DCIS predicted a more rapid progression
to invasive carcinoma [26, 27]. It has been suggested that
HER2 promotes the expression of factors that enhances
invasion [26, 27]. Others theorized that HER2 expression
might be upregulated in the early stages of invasion and
downregulated again in the invasive stage of the tumor [26].
Clonal evolution may also give rise to HER2 negative clones
that develop invasive capabilities [17]. The increased rate of
detection of high-grade DCIS by screening mammography
may also contribute to the higher prevalence of HER2-posi-
tive pDCIS [28].
Although we did not examine the expression of basal
markers in the triple negative tumors, the majority of them
have been shown to have basal phenotypes [29]. The preva-
lence of basal subtype pDCIS was 8% in a population-based
study by Livasy et al. compared to 20% in IBCA [12, 22].
Othershavealsoshownsimilarﬁndings[13].Ithasbeensug-
gested that basal-like pDCIS may have a short in situ phase
[12]. This may explain their lower prevalence and the dif-
ﬁculty in identifying DCIS component in basal IBCA. Dabbs
et al. demonstrated that the DCIS component in basal like
IBCA was very focal and comprised a small percentage
(<10%) of the entire tumor [30].
The lower ER, PR and HER2 expression in some IBCA
compared to pDCIS as shown in this study may explain the
higher prevalence of triple negative tumors in the former.
This may support the theory that triple negative IBCA may
be an acquired phenotype that evolved from either a luminal
Bo rH E R 2s u b t y p eo fD C I S[ 12]. It is also plausible that
tumor progression may be associated with emergence of
clones that have molecular signatures diﬀerent from the cell
of origin [17]. The progression to steroid and HER2 inde-
pendence in some IBCA may also be due to the ability of
some tumors to constitutionally express autocrine growth
factors making them less hormone or HER2 dependent. We
didnotanalyzebasalmarkerexpressioninourtriplenegative
tumors; it is conceivable that some may have expression
proﬁles that are diﬀerent from the true basal phenotype. It is
well known that triple negative tumors are a heterogeneous
group with diverse morphologic and molecular proﬁles [29].
Ki67 index has been shown to have prognostic signiﬁ-
cance in breast cancer [8, 11]. However, there is lack of6 International Journal of Breast Cancer
uniformity in reporting Ki67 values due to diﬀerent tech-
niquesandcutoﬀvalues[11].Moreover,intratumoralheter-
ogeneity in proliferation is another reason for the variability
in the Ki67 index [31]. Quantitative assessment of Ki67
expression by image analysis can provide accurate estima-
tion of the proliferation index. We found that IBCA had
signiﬁcantly higher proliferation compared to pDCIS. Ma
et al. [32] showed signiﬁcantly higher Ki67 in invasive ductal
carcinoma compared to those associated with DCIS.
The highly signiﬁcant association of Ki67 index and
molecularsubtypesofpDCISwithIBCAhasnotbeenshown
previously. Proliferation was highest in the triple negative
tumors followed by HER2 and luminal B subtypes. Luminal
A had the lowest proliferation (<10%). Others have shown
only a modest increase in Ki67 index using tissue microarray
[8]. However, tissue microarray may lead to underestimation
of proliferation, which can vary in diﬀerent areas of the
tumor [31].
Thediﬀerencesinproliferativeactivityamongthemolec-
ular subtypes of invasive carcinoma have been shown in gene
microarray studies [6, 10, 11]. We have demonstrated for the
ﬁrst time the relationship between proliferation and molecu-
lar subtypes of both pDCIS and IBCA using Ki67 expression
byroutineIHC.Additionally,theKi67indicesintheluminal-
HER2, HER2, and triple negative subtypes of IBCA were
signiﬁcantly higher compared to similar subtypes of pDCIS.
The association between increased proliferation and
DCIS progression has been elucidated by Ma et al., where
genes involved in cell proliferation and DNA repair were
expressedathigherlevelinhigh-gradeDCIS,whichwerefur-
ther elevated in IBCA revealing a link between proliferation,
tumorgrade,and invasion [32].Additionally,stromalfactors
may play a critical role in inﬂuencing tumor growth. It is
known that tumor cells can modify the stromal environment
to produce bioactive factors that enhance proliferation,
survival, and invasion [33, 34].
One limitation of this study is that we did not analyze the
DCIS component of the IBCA for comparison with pDCIS
since this is a retrospective analysis. Several studies have
shown no diﬀerences in the biomarker expression in the
DCIS component of IBCA versus IBCA only [17, 35]. We
did not include basal markers for further characterization
of the triple negative tumors. The main strengths of this
study were the use of whole tumor sections and automated
imageanalysisforquantiﬁcationofbiomarkers.Additionally,
biomarkersanalysiswereperformedprospectivelyatthetime
of diagnosis; this may have reduced the bias associated with
sample collection and evaluation. This study comprised a
large number of pDCIS cases where a detailed analysis of





Contrary to previous observation, we have shown that inva-
sion is associated with signiﬁcant increase in Ki67 index and
decrease in ER, PR, and HER2 expression. Although most
breast carcinomas maintain their phenotype during tumor
progression, in some there is a change in phenotype possibly
as aresult of clonal evolution. Stromalfactorsmay also play a
role in inﬂuencing tumor growth and biomarker expression.
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